RNS Number : 6375G
Thalia Therapeutics PLC
02 June 2026

2 June 2026

Thalia Therapeutics plc

("Thalia" or the "Company")

CEO Interview: Building a Differentiated RNA Therapeutics Company

Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA therapeutics, is pleased to announce the release of a new video interview with Chief Executive Officer, Dr David Solomon, speaking with BioHub.

In the interview, Dr Solomon discusses the significant room for innovation in RNA therapeutics and how Thalia is positioning itself in this rapidly expanding market to develop differentiated next-generation RNA Therapeutics.

In particular, the discussion also explores Thalia's differentiated approach to treating cardiovascular disease, with a long-acting preclinical candidate that addresses two independent risk factors of cardiovascular disease simultaneously, PCSK9 and Lp(a), offering the potential for additive or synergistic benefits.

The interview is available to watch via the Company's website at: https://investors.thaliatx.com/activity-updates/epjN8P-thalia-tx-on-biohub

There is growing interest in genetically targeted approaches to cardiovascular disease and PCSK9-targeted therapies, as reflected in recent clinical research published in The New England Journal of Medicine here: https://www.nejm.org/doi/10.1056/NEJMoa2601283

- Ends -

For more information please contact:

Thalia Therapeutics plc
Dr David H Solomon, Chief Executive Officer — Via Thalia Investor Hub
https://investors.thaliatx.com/link/eNbqpe

SP Angel Corporate Finance LLP — Tel: +44 (0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Turner Pope Investments (TPI) Limited Tel: +44 (0)20 3657 0050
Joint Broker
Andy Thacker
Guy McDougall

Northstar Communications Tel: +44 (0)20 7183 2463
Investor relations and Communications
Sarah Hollins

Cohesion Bureau
Investor relations and Communications Tel: +44 (0)7483 284853
Mary-Ann Chang

About Thalia Therapeutics plc

Thalia Therapeutics is a pre-clinical biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. With a growing, differentiated pipeline, de-risked by validated therapeutic targets, we aim to treat diseases at the source by silencing or modifying the genes that cause or contribute to them.

Our preclinical bispecific siRNA is a potentially long-acting treatment for atherosclerotic cardiovascular disease, which addresses two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec®, offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics.

For further information visit www.thaliatx.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAAKBBPOBKKNAK